Febrile Neutropenia - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：57頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Febrile Neutropenia - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Febrile Neutropenia - Pipeline Review, H1 2014’, provides an overview of the Febrile Neutropenia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Febrile Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Febrile Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Febrile Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Febrile Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Febrile Neutropenia - Pipeline Review, H1 2014’, provides an overview of the Febrile Neutropenia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Febrile Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Febrile Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Febrile Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Febrile Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Febrile Neutropenia Overview 7
Therapeutics Development 8
Pipeline Products for Febrile Neutropenia - Overview 8
Pipeline Products for Febrile Neutropenia - Comparative Analysis 9
Febrile Neutropenia - Therapeutics under Development by Companies 10
Febrile Neutropenia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Febrile Neutropenia - Products under Development by Companies 16
Febrile Neutropenia - Companies Involved in Therapeutics Development 17
Hospira, Inc. 17
Amgen Inc. 18
Eli Lilly and Company 19
Biocon Limited 20
Richter Gedeon Nyrt. 21
Sandoz International GmbH 22
Taiho Pharmaceutical Co., Ltd. 23
Sandoz Inc. 24
Xenetic Biosciences plc 25
USV Limited 26
Aequus BioPharma, Inc. 27
Febrile Neutropenia - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
pegfilgrastim - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
vancomycin hydrochoride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(piperacillin sodium + tazobactam sodium) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
filgrastim biosimilar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pegfilgrastim biosimilar - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pegfilgrastim - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
filgrastim - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pegfilgrastim biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pegfilgrastim biosimilar - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Stimuxen - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
filgrastim biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pegfilgrastim biosimilar - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Febrile Neutropenia - Recent Pipeline Updates 52
Febrile Neutropenia - Product Development Milestones 53
Featured News & Press Releases 53
Aug 08, 2013: European Commission grants marketing authorization for Teva's Lonquex 53
Jun 27, 2013: Kyowa Hakko Kirin Submits Application For Approval In Japan For Sustained-duration G-CSF Product 53
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 54
Nov 02, 2010: Nektar Signs $50m Manufacturing And Supply Agreement With Amgen 55
Nov 20, 2008: Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Zarzio 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57
List of Tables
Number of Products under Development for Febrile Neutropenia, H1 2014 8
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Comparative Analysis by Unknown Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Febrile Neutropenia - Pipeline by Hospira, Inc., H1 2014 17
Febrile Neutropenia - Pipeline by Amgen Inc., H1 2014 18
Febrile Neutropenia - Pipeline by Eli Lilly and Company, H1 2014 19
Febrile Neutropenia - Pipeline by Biocon Limited, H1 2014 20
Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2014 21
Febrile Neutropenia - Pipeline by Sandoz International GmbH, H1 2014 22
Febrile Neutropenia - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 23
Febrile Neutropenia - Pipeline by Sandoz Inc., H1 2014 24
Febrile Neutropenia - Pipeline by Xenetic Biosciences plc, H1 2014 25
Febrile Neutropenia - Pipeline by USV Limited, H1 2014 26
Febrile Neutropenia - Pipeline by Aequus BioPharma, Inc., H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Assessment by Combination Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 31
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Febrile Neutropenia Therapeutics - Recent Pipeline Updates, H1 2014 52
List of Figures
Number of Products under Development for Febrile Neutropenia, H1 2014 8
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Target, H1 2014 31
Number of Products by Top 10 Mechanism of Action, H1 2014 32
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 33
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Febrile Neutropenia Overview 7
Therapeutics Development 8
Pipeline Products for Febrile Neutropenia - Overview 8
Pipeline Products for Febrile Neutropenia - Comparative Analysis 9
Febrile Neutropenia - Therapeutics under Development by Companies 10
Febrile Neutropenia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Febrile Neutropenia - Products under Development by Companies 16
Febrile Neutropenia - Companies Involved in Therapeutics Development 17
Hospira, Inc. 17
Amgen Inc. 18
Eli Lilly and Company 19
Biocon Limited 20
Richter Gedeon Nyrt. 21
Sandoz International GmbH 22
Taiho Pharmaceutical Co., Ltd. 23
Sandoz Inc. 24
Xenetic Biosciences plc 25
USV Limited 26
Aequus BioPharma, Inc. 27
Febrile Neutropenia - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
pegfilgrastim - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
vancomycin hydrochoride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(piperacillin sodium + tazobactam sodium) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
filgrastim biosimilar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pegfilgrastim biosimilar - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pegfilgrastim - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
filgrastim - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pegfilgrastim biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pegfilgrastim biosimilar - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Stimuxen - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
filgrastim biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pegfilgrastim biosimilar - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Febrile Neutropenia - Recent Pipeline Updates 52
Febrile Neutropenia - Product Development Milestones 53
Featured News & Press Releases 53
Aug 08, 2013: European Commission grants marketing authorization for Teva's Lonquex 53
Jun 27, 2013: Kyowa Hakko Kirin Submits Application For Approval In Japan For Sustained-duration G-CSF Product 53
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 54
Nov 02, 2010: Nektar Signs $50m Manufacturing And Supply Agreement With Amgen 55
Nov 20, 2008: Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Zarzio 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57
List of Tables
Number of Products under Development for Febrile Neutropenia, H1 2014 8
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Comparative Analysis by Unknown Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Febrile Neutropenia - Pipeline by Hospira, Inc., H1 2014 17
Febrile Neutropenia - Pipeline by Amgen Inc., H1 2014 18
Febrile Neutropenia - Pipeline by Eli Lilly and Company, H1 2014 19
Febrile Neutropenia - Pipeline by Biocon Limited, H1 2014 20
Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2014 21
Febrile Neutropenia - Pipeline by Sandoz International GmbH, H1 2014 22
Febrile Neutropenia - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 23
Febrile Neutropenia - Pipeline by Sandoz Inc., H1 2014 24
Febrile Neutropenia - Pipeline by Xenetic Biosciences plc, H1 2014 25
Febrile Neutropenia - Pipeline by USV Limited, H1 2014 26
Febrile Neutropenia - Pipeline by Aequus BioPharma, Inc., H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Assessment by Combination Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 31
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Febrile Neutropenia Therapeutics - Recent Pipeline Updates, H1 2014 52
List of Figures
Number of Products under Development for Febrile Neutropenia, H1 2014 8
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Target, H1 2014 31
Number of Products by Top 10 Mechanism of Action, H1 2014 32
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 33
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
